Protalix BioTherapeutics, Inc. (PLX)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$2.69+3.07%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PLX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the trailing year it converted 6.10x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 54% of the time over the next year (vs 44% for the rest of the cohort, n=2525).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
8 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.